If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Pregabalin Effective in Patients With Refractory Severe Generalised Anxiety Disorder: Presented at EPA By Jenny Powers MUNICH, Germany -- March 5, 2010 -- A >50% reduction of baseline anxiety scores and baseline depressive symptoms was seen at 6 months in patients with severe, refractory generalised anxiety disorder (GAD) receiving pregabalin therapy, according to a study presented here at the European Psychiatry Association (EPA) 18th European Congress of Psychiatry. José M. Olivares, MD, Department of Psychiatry, Complejo Hospitalario Universitario, Vigo, Spain, reported results here on February 28 from an analysis of a cohort of the ADAN study, a multicentre prospective and observational study in 618 Spanish outpatient clinics. The objective was to analyse the effect of pregabalin on anxiety and depression symptoms in patients with severe refractory GAD and concomitant severe depressive disorder. The analysis involved 159 patients who were pregabalin-naïve and had been refractory to a previous course of benzodiazepines and/or antidepressive drugs and who displayed severe symptoms of anxiety defined as Hamilton Rating Scale for Anxiety (HAM-A) >=24 and depression defined as Montgomery-Asberg Depression Rating Scale (MADRS) >=35. At 6 months of pregabalin treatment (mean dose 223.1 mg/day), HAM-A scores were reduced from baseline by 57.9% (35.5 +- 5.8 to 14.8 +- 9.4; P < .001, effect size 3.57). The responder rates with pregabalin treatment (>50% reduction of baseline score in HAM-A scale) were >62% for psychic anxiety, somatic anxiety, and total anxiety scores. Pregabalin therapy reduced baseline depression scores by a mean of 58.1% (MADRS 39.4 +- 4.3 to 16.5 +- 10.3; P < .001, effect size 5.33). The responder rate (>=50% reduction of baseline score on MADRS scale) regarding the severity level of depression symptoms was 62.9%. At 6-months, 34.4% of patients had no symptoms of anxiety and 40.9% showed no symptoms of depression (P < .001). The researchers concluded that pregabalin had a significant effect on the symptoms of anxiety and depression experienced by patients with severe refractory GAD and comorbid severe depressive disorder. Funding for this study was provided by Pfizer Espana. [Presentation title: Effect of Pregabalin on Patients With Refractory-Severe Generalized Anxiety Disorder and Concomitant Severe Symptoms of Depression in Daily Medical Practice. Abstract P01-153]
|
